A clinical trial evaluating liraglutide, titled "Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome," updated its status to completed as of August 21, 2026. The study, registered as NCT05965908, is a Phase 3 trial. Liraglutide is an approved compound, and this trial examined its use specifically in obese women with polycystic ovary syndrome. The completion status indicates the trial has concluded, though this update does not include any reported results or outcome data. No efficacy or safety findings have been disclosed as part of this status change. Further details about the trial design, methodology, and eventual results can be found through the official clinical trial registry listing. Readers interested in the broader context of liraglutide, including its approved uses and regulatory history, can consult the compound overview for additional background information.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT05965908"]